Cardior posts Phase 2 HF-REVERT results for CDR132L in post-MI heart failure
Cardior Pharmaceuticals reported completed Phase 2 results for CDR132L, an antisense drug targeting miR-132, in patients with reduced ejection fraction after heart attack.
Cardior Pharmaceuticals had one notable update this week, with results posted for its lead cardiac program.
- Cardior's Phase 2 "HF-REVERT" trial (NCT05350969) tested CDR132L, described as a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132)1, in patients with left ventricular ejection fraction of 45% or less after myocardial infarction. The study was randomized with an enrollment of 294 participants1 across two CDR132L dose arms and placebo, and results were first posted on 2026-08-26 after the study reached completion with a primary completion date of 2024-09-26 and study completion of 2025-03-17.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.